Precision Therapeutics recaps, now Helomics

Oncology diagnostics play Helomics Corp. (Pittsburgh, Pa.) recapitalized with a $60 million investment from HealthCare Royalty Partners and changed its name from Precision Therapeutics Inc. The company also named as its new CEO Neil Campbell, formerly CEO of SuperNova Diagnostics Inc. (Germantown, Md.) and veteran of Abbott Laboratories (NYSE:ABT) and Celera Genomics Corp., acquired by Quest Diagnostics Inc. (NYSE:DGX) in 2011.

Helomics intends to develop an expanded platform of next-generation personalized diagnostics, according to Campbell. ...